Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Neoplasm Metastasis 3Breast Neoplasms 3Ovarian Neoplasms 2Mesothelioma 1Endometrial Neoplasms 1Carcinosarcoma 1

Interventions

pembrolizumab 9Nivolumab 4budigalimab 2belinostat 2Pemetrexed 2Ipilimumab 2Cyclophosphamide 2Cisplatin 2Carboplatin 2venetoclax 1tocilizumab 1tislelizumab 1talazoparib 1spartalizumab 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1obinutuzumab 1naptumomab estafenatox 1fludarabine 1epacadostat 1enzalutamide 1durvalumab 1cabozantinib 1abemaciclib 1Valacyclovir 1Sorafenib 1Sirolimus 1Quality of Life 1Plicamycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × DCC-2036 × Breast × Clear all
NCT03717415 2024-12-27

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Deciphera Pharmaceuticals, LLC

Phase 1/2 Terminated
70 enrolled 24 charts
BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡